349 related articles for article (PubMed ID: 23487815)
1. When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.
Worth PF
Pract Neurol; 2013 Jun; 13(3):140-52. PubMed ID: 23487815
[TBL] [Abstract][Full Text] [Related]
2. [Treatment possibilities in advanced Parkinson's disease].
Takáts A; Nagy H; Radics P; Tóth A; Tamás G
Ideggyogy Sz; 2013 Nov; 66(11-12):365-71. PubMed ID: 24555235
[TBL] [Abstract][Full Text] [Related]
3. Advanced Parkinson's disease: clinical characteristics and treatment. Part II.
Kulisevsky J; Luquin MR; Arbelo JM; Burguera JA; Carrillo F; Castro A; Chacón J; García-Ruiz PJ; Lezcano E; Mir P; Martinez-Castrillo JC; Martínez-Torres I; Puente V; Sesar A; Valldeoriola-Serra F; Yañez R
Neurologia; 2013; 28(9):558-83. PubMed ID: 23880230
[TBL] [Abstract][Full Text] [Related]
4. Use of advanced therapies for Parkinson's disease in Norway.
Ezat B; Pihlstrøm L; Aasly J; Tysnes OB; Egge A; Dietrichs E
Tidsskr Nor Laegeforen; 2017 May; 137(9):619-623. PubMed ID: 28468476
[TBL] [Abstract][Full Text] [Related]
5. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
Fernandez HH; Odin P
Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823
[TBL] [Abstract][Full Text] [Related]
6. [Selection of the optimal device-aided therapy in Parkinson's disease].
Kovács N; Aschermann Z; Juhász A; Harmat M; Pintér D; Janszky J
Ideggyogy Sz; 2019 Jan; 72(1-2):5-11. PubMed ID: 30785241
[TBL] [Abstract][Full Text] [Related]
7. Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease.
Merola A; Zibetti M; Angrisano S; Rizzi L; Lanotte M; Lopiano L
Mov Disord; 2011 Mar; 26(4):664-70. PubMed ID: 21469197
[TBL] [Abstract][Full Text] [Related]
8. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
[TBL] [Abstract][Full Text] [Related]
9. A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies.
Salles PA; Liao J; Shuaib U; Mata IF; Fernandez HH
J Parkinsons Dis; 2022; 12(6):1703-1725. PubMed ID: 35662127
[TBL] [Abstract][Full Text] [Related]
10. [Device-aided therapies in advanced Parkinson's disease].
Timofeeva AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):54-60. PubMed ID: 28139627
[TBL] [Abstract][Full Text] [Related]
11. The role of subcutaneous infusion of apomorphine in Parkinson's disease.
Wenzel K; Homann CN; Fabbrini G; Colosimo C
Expert Rev Neurother; 2014 Jul; 14(7):833-43. PubMed ID: 24917215
[TBL] [Abstract][Full Text] [Related]
12. Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy.
Sahlström T; Eklund M; Timpka J; Henriksen T; Nyholm D; Odin P
Acta Neurol Scand; 2018 Jul; 138(1):78-84. PubMed ID: 29569237
[TBL] [Abstract][Full Text] [Related]
13. [Parkinson's disease - the future of invasive therapy].
Deuschl G
Fortschr Neurol Psychiatr; 2010 Mar; 78 Suppl 1():S16-9. PubMed ID: 20195935
[TBL] [Abstract][Full Text] [Related]
14. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
[TBL] [Abstract][Full Text] [Related]
15. The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
Dijk JM; Espay AJ; Katzenschlager R; de Bie RMA
J Parkinsons Dis; 2020; 10(s1):S65-S73. PubMed ID: 32651333
[TBL] [Abstract][Full Text] [Related]
16. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
Toth A; Nagy H; Wacha J; Bereczki D; Takáts A
Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
[TBL] [Abstract][Full Text] [Related]
17. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.
Antonini A; Stoessl AJ; Kleinman LS; Skalicky AM; Marshall TS; Sail KR; Onuk K; Odin PLA
Curr Med Res Opin; 2018 Dec; 34(12):2063-2073. PubMed ID: 30016901
[TBL] [Abstract][Full Text] [Related]
18. Device-aided therapies for advanced Parkinson disease: insights from an international survey.
Marsili L; Bologna M; Miyasaki JM; Colosimo C
Neurol Sci; 2021 Jul; 42(7):2961-2964. PubMed ID: 33550525
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.
Clarke CE; Worth P; Grosset D; Stewart D
Parkinsonism Relat Disord; 2009 Dec; 15(10):728-41. PubMed ID: 19805000
[TBL] [Abstract][Full Text] [Related]
20. [Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013].
Aschermann Z; Kovács N; Komoly S
Ideggyogy Sz; 2013 May; 66(5-6):209-10. PubMed ID: 23909024
[No Abstract] [Full Text] [Related]
[Next] [New Search]
